Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
CNS & Neurological Disorders - Drug Targets
Title:Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
Volume: 13 Issue: 6
Author(s): Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrion, Jose A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva
Affiliation:
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Export Options
About this article
Cite this article as:
Schier R. de Mello Alexandre, Ribeiro P. de Oliveira Natalia, Coutinho S. Danielle, Machado Sergio, Arias-Carrion Oscar, Crippa A. Jose, Zuardi W. Antonio, Nardi E. Antonio and Silva C. Adriana, Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612114838
DOI https://dx.doi.org/10.2174/1871527313666140612114838 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Hyperthermia for Cancer Treatment: Recent Patents Review
Recent Patents on Anti-Cancer Drug Discovery The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery The Molecular Basis of Neural Memory. Part 4. “Binary” Computation vs “Multinary” Mentation
Neuroscience and Biomedical Engineering (Discontinued) Restless Legs Syndrome After Single Low Dose Quetiapine Administration
Current Drug Safety Commentary (Research Highlights: WNT-erizing Against Neuropathic Pain)
CNS & Neurological Disorders - Drug Targets Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Chelators for the Twenty First Century: New Treatments for Iron and Copper Mediated Inflammatory and Neurological Disorders
Current Drug Delivery Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Differences in Kynurenine Metabolism During Depressive, Manic, and Euthymic Phases of Bipolar Affective Disorder
Current Topics in Medicinal Chemistry Immune System Modulators with Antidepressant Effects: Evidence from Animal Models
CNS & Neurological Disorders - Drug Targets New Targeted Treatments for Fragile X Syndrome
Current Pediatric Reviews Sense and Sensibility When Prescribing ‘Off-Label’ to Psychiatric Patients
Current Pharmaceutical Design Raman Spectroscopy as a Novel Technology in Forensic Toxicological Analyses
Current Analytical Chemistry Preparation and Certification of Sulfamethoxazole Reference Material by Mass Balance Method and Differential Scanning Calorimetry
Current Analytical Chemistry Structure-Activity Relationships in Peptide-Antibody Complexes: Implications for Epitope Prediction and Development of Synthetic Peptide Vaccines
Current Medicinal Chemistry Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Conformational Analysis of Opioid Peptides in the Solid States and the Membrane Environments by NMR Spectroscopy
Current Topics in Medicinal Chemistry